IL-13/IL-13RA2 Signaling Promotes Colorectal Cancer Stem Cell Tumorigenesis by Inducing Ubiquitinated Degradation of P53
Overview
Authors
Affiliations
Cancer stem cells (CSCs) are considered tumor-initiating cells and the main drivers of disease progression. Targeting these rare cancer cells, however, remains challenging with respect to therapeutic benefit. Here, we report the up-regulation of IL-13RA2 expression in colorectal cancer (CRC) tissues and spheroid cells. The expression of IL-13RA2 was positively correlated with canonical stemness markers in CRC. We further demonstrated that the level of IL-13 was up-regulated in the serum of CRC patients. Biologically, recombinant IL-13 (rIL-13) stimulation promoted the sphere formation, proliferation, and migration of CRC cells and enhanced tumorigenesis . This phenotype could be reversed by knocking down IL-13RA2. Mechanistically, IL-13 activated autophagy by inducing LC3I/LC3II transformation in CRC-CSCs, which was crucial for the biological functions of IL-13. We further demonstrated that IL-13RA2 acted as a modular link of the E3 ligase UBE3C and the substrate p53 protein, enhancing the interaction of UBE3C and p53, thereby inducing the K48-linked ubiquitination of p53. In conclusion, the IL-13/IL-13RA2 signaling cascade promotes CRC-CSC self-renewal and tumorigenesis by inducing p53 ubiquitination, adding an important layer to the connection between IL-13 and p53, which can be translated into novel targeted therapies.
Alobaidi R, Islam N, Olkey T, Haribabu Y, Shamo M, Sykora P Cells. 2025; 14(4).
PMID: 39996721 PMC: 11852824. DOI: 10.3390/cells14040248.
Detection of Cancer Stem Cells from Patient Samples.
Hakala S, Hamalainen A, Sandelin S, Giannareas N, Narva E Cells. 2025; 14(2).
PMID: 39851576 PMC: 11764358. DOI: 10.3390/cells14020148.
Ingram J, McQuade V, Weiss J, Womble J, Ihrie M, Zhao K J Allergy Clin Immunol. 2024; 155(3):819-833.e10.
PMID: 39581293 PMC: 11875949. DOI: 10.1016/j.jaci.2024.10.039.
Li X, Chen M, Cao J, Chen X, Song H, Shi S Heliyon. 2024; 10(17):e37002.
PMID: 39286156 PMC: 11402917. DOI: 10.1016/j.heliyon.2024.e37002.
Liu Z, Ma T, Li J, Ren W, Zhang Z Oncol Res. 2024; 32(9):1453-1465.
PMID: 39220137 PMC: 11361910. DOI: 10.32604/or.2024.048315.